Piramal Pharma: Business Overview & Financial Analysis
Piramal Pharma Limited is a global pharmaceutical enterprise headquartered in Mumbai, Maharashtra. Promoted by the Piramal Group, the company operates an integrated healthcare business spanning contract development and manufacturing services (CDMO), complex hospital generics, and India consumer healthcare products. With manufacturing and R&D facilities across India, North America, and Europe, Piramal Pharma supplies small molecule APIs, finished dosage forms, inhalation anaesthetics, injectable diagnostics, and OTC consumer health products to customers across 100+ international markets.
Revenue Breakdown by Business Segment of Piramal Pharma (Q1 FY27)
Piramal Pharma categorises its operational turnover across CDMO services, complex hospital generics, and consumer healthcare products.
- Contract Development & Manufacturing Organisation (CDMO) – 68.0% of Total Revenue
- Complex Hospital Generics (CHG) – 22.0% of Total Revenue
- India Consumer Healthcare (ICH) – 10.0% of Total Revenue
- Total Consolidated Revenue from Operations (Q1 FY27) – Rs 2,120.40 crore (+9.8% YoY)
The CDMO division serves as the primary revenue engine, supplying integrated drug substance and drug product services to global innovator pharmaceutical companies. Complex Hospital Generics and India Consumer Healthcare verticals deliver high-margin niche generic solutions and branded OTC consumer products.
Revenue Breakdown by Geographic Market of Piramal Pharma (FY26)
Piramal Pharma maintains a diversified global delivery footprint with primary revenue contributions coming from regulated western markets.
- North America – 42.0% of Total Revenue
- Europe – 31.0% of Total Revenue
- India (Domestic Market) – 15.0% of Total Revenue
- Rest of the World (RoW) – 12.0% of Total Revenue
Regulated markets across North America and Europe generate over seven-tenths of total consolidated turnover. Domestic Indian operations comprise consumer healthcare sales and local commercialization of complex generic formulations.
CDMO Business Service Portfolio & Capabilities of Piramal Pharma (Q1 FY27)
Piramal Pharma offers specialized end-to-end development and commercial manufacturing capabilities across complex therapeutic platforms.
- High Potency APIs (HPAPI) & Antibody Drug Conjugates (ADCs) – Grangemouth (UK) and Riverview (US) facilities
- Commercial Small Molecule APIs – Digwal (India) and Ennore (India) plants
- Sterile Injectables & Fill-Finish – Lexington (US) and Ahmedabad (India) facilities
- On-Off-Patent Commercial Order Book – >45% of CDMO revenues derived from patented on-market commercial drugs
Specialized high-margin services such as Antibody Drug Conjugates (ADCs) and High Potency APIs lead CDMO revenue growth. Patented commercial drug manufacturing supplies long-term multi-year revenue stability.
Complex Hospital Generics (CHG) Portfolio & Scale of Piramal Pharma (FY26)
Piramal Pharma commands global market positions across inhalation anaesthetics and injectable hospital products.
- Inhalation Anaesthetics Product Line – Sevoflurane, Isoflurane, and Desflurane
- Global Inhalation Anaesthetics Market Position – #1 or #2 Position globally across key markets
- Injectable Diagnostics & Pain Management – Intrathecal baclofen, injectable pain care, and contrast media
- Direct Hospital Distribution Footprint – Supplying 6,000+ hospitals across 100+ countries
The company holds leadership positions in inhalation anaesthetics worldwide, backed by direct sales teams in North America and Europe. Hospital product lines benefit from high entry barriers due to complex sterile manufacturing and specialized sales channels.
India Consumer Healthcare (ICH) Brand Portfolio of Piramal Pharma (Q1 FY27)
Piramal Pharma manages a portfolio of OTC brands in skin care, gastrointestinal health, analgesics, and women's health in India.
- Power Brands Portfolio – Lacto Calamine, i-Pill, Polycrol, Tetmosol, and Sloan's
- E-Commerce Sales Share – 16.0% of total ICH turnover
- Direct Retail Distribution Reach – 320,000+ chemist outlets across India
- New Product Launch Revenue Share – ~14% of ICH revenues derived from products launched in last 36 months
Key power brands like Lacto Calamine and i-Pill drive consumer healthcare growth across domestic retail channels. E-commerce platforms process 16% of total division sales, complementing a physical retail distribution reach of 320,000+ outlets.
Global Manufacturing Facilities & Regulatory Status of Piramal Pharma (Q1 FY27)
Piramal Pharma operates a global network of 15 manufacturing and R&D facilities compliant with international regulatory bodies.
- Total Operational Facilities – 15 manufacturing and development sites globally
- USFDA Compliant Plants Count – 11 facilities cleared by USFDA
- Key Plant Locations – Digwal, Ennore, Ahmedabad, Lexington (US), Riverview (US), Grangemouth (UK), and Morpeth (UK)
- Regulatory Track Record – Successful completion of multiple USFDA, MHRA, and PMDA regulatory audits without critical observations
A global footprint of 15 manufacturing units supports dual-sourcing options for global innovator pharmaceutical clients. High regulatory compliance standards across USFDA-cleared facilities protect ongoing supply contracts.
Latest Quarterly Financial Performance of Piramal Pharma (Q1 FY27)
Piramal Pharma recorded steady top-line revenue expansion and operating EBITDA growth during the first quarter of FY27.
- Consolidated Revenue from Operations – Rs 2,120.40 crore (+9.8% YoY)
- Consolidated Operating EBITDA – Rs 285.20 crore (+18.4% YoY)
- Operating EBITDA Margin – 13.4% (+98 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 32.50 crore (vs Net Loss in Q1 FY26)
- CDMO Segment Revenue Growth – +12.2% YoY
First-quarter operating revenue rose 9.8% year-on-year to Rs 2,120.40 crore, supported by CDMO order execution and hospital generics volume dispatches. Operating EBITDA expanded 18.4% to Rs 285.20 crore, delivering a net profit of Rs 32.50 crore.
Consolidated Annual Financial Performance of Piramal Pharma (FY26)
Piramal Pharma achieved revenue growth and a turnaround in full-year net profitability in FY26.
- Full Year Consolidated Revenue from Operations – Rs 8,350.20 crore (+12.5% YoY)
- Full Year Operating EBITDA – Rs 1,280.40 crore (+21.2% YoY)
- Full Year Operating EBITDA Margin – 15.3% (+110 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 215.40 crore (vs Rs 82.10 crore in FY25)
Full-year operating turnover crossed Rs 8,350 crore in FY26, as Net Profit After Tax expanded to Rs 215.40 crore. Annual financial performance was supported by CDMO operational leverage and cost-efficiency initiatives.
Financial Position & Capital Structure Metrics of Piramal Pharma (Q1 FY27)
Piramal Pharma maintains a balance sheet structure supported by debt reduction and operational cash generation.
- Consolidated Net Debt – Rs 3,750 crore (reduced from Rs 4,220 crore in FY25)
- Net Debt to Operating EBITDA Ratio – 2.82x (vs 3.45x in FY25)
- Average Cost of Debt – 7.85%
- Return on Capital Employed (ROCE) – 9.2%
- Return on Equity (ROE) – 6.5%
Consolidated net debt compressed to Rs 3,750 crore at the close of Q1 FY27, lowering the Net Debt to EBITDA ratio to 2.82x. Deleveraging initiatives continue to reduce annual finance costs across global debt facilities.
Management Commentary & Strategic Outlook of Piramal Pharma (Q1 FY27 Concall)
Management commentary highlights strategic priorities centered on CDMO order book execution, margin expansion, and balance sheet deleveraging.
- Management targets achieving low-to-mid teens revenue growth in Constant Currency terms for full financial year FY27.
- Operating EBITDA margins are guided to expand toward the 16.5%–17.5% corridor during FY27 through operational leverage.
- CDMO growth will be driven by high-margin ADC, HPAPI, and sterile injectable capacity utilization.
- Net debt reduction remains a priority, targeting Net Debt to EBITDA below 2.5x by the end of FY27.
- Annual capital expenditure is budgeted at Rs 550–600 crore, funded primarily through internal cash accruals.
Management anticipates strong demand for differentiated CDMO services and hospital generic solutions across regulated markets. Operational focus centers on driving capacity utilization across newly expanded sites, optimizing product mix, and accelerating debt reduction.
Want to filter out stocks using your own financial benchmarks? You can use the Stock Screener on Finology Ticker to identify and compare companies based on specific growth and efficiency metrics.
Sources & References
- Piramal Pharma Limited Q1 FY27 Earnings Conference Call Transcript (July/August 2026)
- Piramal Pharma Limited Q1 FY27 Unaudited Financial Results Release & Investor Presentation (July/August 2026)
- Piramal Pharma Limited Q4 & Full Year FY26 Consolidated Financial Disclosures (May 2026)
- BSE India & NSE Official Corporate Announcements for Piramal Pharma Limited
- Ticker Finology Piramal Pharma Page
Disclaimer
The information presented above on Piramal Pharma Limited has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Piramal Pharma Limited page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.